218 related articles for article (PubMed ID: 30758237)
1. Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison.
Vargas C; Balmaceda C; Rodríguez F; Rojas R; Giglio A; Espinoza MA
Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):609-617. PubMed ID: 30758237
[No Abstract] [Full Text] [Related]
2. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.
Nazha S; Tanguay S; Kapoor A; Jewett M; Kollmannsberger C; Wood L; Bjarnason GAG; Heng D; Soulières D; Reaume MN; Basappa N; Lévesque E; Dragomir A
Clin Drug Investig; 2018 Dec; 38(12):1155-1165. PubMed ID: 30267257
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
Capri S; Porta C; Delea TE
Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
Amdahl J; Diaz J; Sharma A; Park J; Chandiwana D; Delea TE
PLoS One; 2017; 12(6):e0175920. PubMed ID: 28636648
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain.
Villa G; Hernández-Pastor LJ
BMC Cancer; 2013 Sep; 13():399. PubMed ID: 24004638
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
Remák E; Charbonneau C; Négrier S; Kim ST; Motzer RJ
J Clin Oncol; 2008 Aug; 26(24):3995-4000. PubMed ID: 18711190
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.
Paz-Ares L; del Muro JG; Grande E; Díaz S
J Clin Pharm Ther; 2010 Aug; 35(4):429-38. PubMed ID: 20831545
[TBL] [Abstract][Full Text] [Related]
10. An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy.
Capri S; Porta C; Condorelli C; Premoli E; Khare A; Kalra M; Modi N; Ratto B
J Med Econ; 2020 Dec; 23(12):1579-1587. PubMed ID: 33079593
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.
Kilonzo M; Hislop J; Elders A; Fraser C; Bissett D; McClinton S; Mowatt G; Vale L
Pharmacoeconomics; 2013 Jan; 31(1):15-24. PubMed ID: 23329590
[TBL] [Abstract][Full Text] [Related]
12. [Cost-effectiveness between pazopanib and sunitinib for metastatic renal cancer from the perspective of the Brazilian Unified National Health System].
Meirelles IO; Couto DHN; Costa RSD
Cad Saude Publica; 2019 Aug; 35(8):e00108218. PubMed ID: 31460611
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
Calvo Aller E; Maroto P; Kreif N; González Larriba JL; López-Brea M; Castellano D; Martí B; Díaz Cerezo S
Clin Transl Oncol; 2011 Dec; 13(12):869-77. PubMed ID: 22126730
[TBL] [Abstract][Full Text] [Related]
14. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore.
Pruis SL; Aziz MIA; Pearce F; Tan MH; Wu DB; Ng K
Int J Technol Assess Health Care; 2019 Jan; 35(2):126-133. PubMed ID: 30854989
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
[TBL] [Abstract][Full Text] [Related]
17. Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
MacLean E; Mardekian J; Cisar LA; Hoang CJ; Harnett J
J Manag Care Spec Pharm; 2016 Aug; 22(8):979-90. PubMed ID: 27459661
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.
Chen J; Hu G; Chen Z; Wan X; Tan C; Zeng X; Cheng Z
Clin Drug Investig; 2019 Oct; 39(10):931-938. PubMed ID: 31250401
[TBL] [Abstract][Full Text] [Related]
20. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.
Wan X; Zhang Y; Tan C; Zeng X; Peng L
JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
